Skip to main content
Erschienen in: European Radiology 1/2018

27.07.2017 | Molecular Imaging

Non-invasive monitoring of the therapeutic response in sorafenib-treated hepatocellular carcinoma based on photoacoustic imaging

verfasst von: Seunghyun Lee, Jung Hoon Kim, Jae Hwan Lee, Jeong Hwa Lee, Joon Koo Han

Erschienen in: European Radiology | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

We investigated the changes of tissue oxygen saturation (sO2) in sorafenib-treated HCC (hepatocelluar carcinoma) mouse models using photoacoustic imaging (PI).

Materials and Methods

Nude mice, implanted with human HCC (HepG2-RFP) cells in the liver, were randomised to the sorafenib-treated group (n = 21) or the control group (n = 20). Tumour volume and sO2 were measured by PI at baseline and then one week later, and radiant efficiency (RE) and therapeutic response were analysed by fluorescence imaging and histologic analysis.

Results

Sorafenib was effective in treating HCC by evaluating necrotic fraction, apoptosis index, and microvessel density (MVD). One week after treatment, the sO2 of HCC and residual healthy liver tissue decreased, and the hypoxia inducible factor-1α (HIF-1α) protein expression of HCC increased, correlating with the apoptosis index. The ΔsO2 in HCC showed a significantly positive correlation with the necrotic fraction and the apoptosis index of tumour and a negative correlation with the MVD of tumour.

Conclusion

Sorafenib treatment results in changes of sO2 in HCC and liver parenchyma and induces the accumulation of HIF-1α by hypoxic environment. sO2 as measured by PI, can be a useful marker for non-invasive monitoring of the therapeutic response in orthotopic HCC mouse models.

Key Points

Hypoxia is a characteristic feature of the tumour microenvironment
It is important to monitor sO 2 in HCC during sorafenib treatment
PI is useful for non-invasive monitoring of sO 2 in HCC.
• ΔsO 2 in HCC showed a significantly correlation with tumour response.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Sun HC, Tang ZY (2004) Angiogenesis in hepatocellular carcinoma: the retrospectives and perspectives. J Cancer Res Clin Oncol 130:307–319CrossRefPubMed Sun HC, Tang ZY (2004) Angiogenesis in hepatocellular carcinoma: the retrospectives and perspectives. J Cancer Res Clin Oncol 130:307–319CrossRefPubMed
3.
Zurück zum Zitat Wigerup C, Pahlman S, Bexell D (2016) Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer. Pharmacol Ther 164:152–169CrossRefPubMed Wigerup C, Pahlman S, Bexell D (2016) Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer. Pharmacol Ther 164:152–169CrossRefPubMed
4.
Zurück zum Zitat Taketomi A (2016) Clinical trials of antiangiogenic therapy for hepatocellular carcinoma. Int J Clin Oncol 21:213–218CrossRefPubMed Taketomi A (2016) Clinical trials of antiangiogenic therapy for hepatocellular carcinoma. Int J Clin Oncol 21:213–218CrossRefPubMed
5.
Zurück zum Zitat McIntyre A, Harris AL (2015) Metabolic and hypoxic adaptation to anti-angiogenic therapy: a target for induced essentiality. EMBO Mol Med 7:368–379CrossRefPubMedCentralPubMed McIntyre A, Harris AL (2015) Metabolic and hypoxic adaptation to anti-angiogenic therapy: a target for induced essentiality. EMBO Mol Med 7:368–379CrossRefPubMedCentralPubMed
6.
Zurück zum Zitat Welker MW, Trojan J (2011) Anti-angiogenesis in hepatocellular carcinoma treatment: Current evidence and future perspectives. World J Gastroenterol 17:3075–3081PubMedCentralPubMed Welker MW, Trojan J (2011) Anti-angiogenesis in hepatocellular carcinoma treatment: Current evidence and future perspectives. World J Gastroenterol 17:3075–3081PubMedCentralPubMed
7.
Zurück zum Zitat Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390CrossRefPubMed Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390CrossRefPubMed
8.
Zurück zum Zitat Yamada D, Kobayashi S, Yamamoto H et al (2012) Role of the hypoxia-related gene, JMJD1A, in hepatocellular carcinoma: clinical impact on recurrence after hepatic resection. Ann Surg Oncol 19(Suppl 3):S355–364CrossRefPubMed Yamada D, Kobayashi S, Yamamoto H et al (2012) Role of the hypoxia-related gene, JMJD1A, in hepatocellular carcinoma: clinical impact on recurrence after hepatic resection. Ann Surg Oncol 19(Suppl 3):S355–364CrossRefPubMed
9.
Zurück zum Zitat Yip C, Blower PJ, Goh V, Landau DB, Cook GJ (2015) Molecular imaging of hypoxia in non-small-cell lung cancer. Eur J Nucl Med Mol Imaging 42:956–976CrossRefPubMed Yip C, Blower PJ, Goh V, Landau DB, Cook GJ (2015) Molecular imaging of hypoxia in non-small-cell lung cancer. Eur J Nucl Med Mol Imaging 42:956–976CrossRefPubMed
10.
Zurück zum Zitat Fatema CN, Zhao SJ, Zhao Y et al (2014) Dual tracer evaluation of dynamic changes in intratumoral hypoxic and proliferative states after radiotherapy of human head and neck cancer xenografts using radiolabeled FMISO and FLT. Bmc Cancer 14 Fatema CN, Zhao SJ, Zhao Y et al (2014) Dual tracer evaluation of dynamic changes in intratumoral hypoxic and proliferative states after radiotherapy of human head and neck cancer xenografts using radiolabeled FMISO and FLT. Bmc Cancer 14
11.
Zurück zum Zitat Raes F, Sobilo J, Le Mee M et al (2016) High Resolution Ultrasound and Photoacoustic Imaging of Orthotopic Lung Cancer in Mice: New Perspectives for Onco-Pharmacology. Plos One 11, e0153532CrossRefPubMedCentralPubMed Raes F, Sobilo J, Le Mee M et al (2016) High Resolution Ultrasound and Photoacoustic Imaging of Orthotopic Lung Cancer in Mice: New Perspectives for Onco-Pharmacology. Plos One 11, e0153532CrossRefPubMedCentralPubMed
12.
Zurück zum Zitat Gerling M, Zhao Y, Nania S et al (2014) Real-time assessment of tissue hypoxia in vivo with combined photoacoustics and high-frequency ultrasound. Theranostics 4:604–613CrossRefPubMedCentralPubMed Gerling M, Zhao Y, Nania S et al (2014) Real-time assessment of tissue hypoxia in vivo with combined photoacoustics and high-frequency ultrasound. Theranostics 4:604–613CrossRefPubMedCentralPubMed
13.
Zurück zum Zitat Needles A, Heinmiller A, Sun J et al (2013) Development and initial application of a fully integrated photoacoustic micro-ultrasound system. IEEE Trans Ultrason Ferroelectr Freq Control 60:888–897CrossRefPubMed Needles A, Heinmiller A, Sun J et al (2013) Development and initial application of a fully integrated photoacoustic micro-ultrasound system. IEEE Trans Ultrason Ferroelectr Freq Control 60:888–897CrossRefPubMed
14.
Zurück zum Zitat Rich LJ, Seshadri M (2015) Photoacoustic imaging of vascular hemodynamics: validation with blood oxygenation level-dependent MR imaging. Radiology 275:110–118CrossRefPubMed Rich LJ, Seshadri M (2015) Photoacoustic imaging of vascular hemodynamics: validation with blood oxygenation level-dependent MR imaging. Radiology 275:110–118CrossRefPubMed
15.
Zurück zum Zitat Murakami M, Zhao S, Zhao Y et al (2012) Evaluation of changes in the tumor microenvironment after sorafenib therapy by sequential histology and 18F-fluoromisonidazole hypoxia imaging in renal cell carcinoma. Int J Oncol 41:1593–1600CrossRefPubMedCentralPubMed Murakami M, Zhao S, Zhao Y et al (2012) Evaluation of changes in the tumor microenvironment after sorafenib therapy by sequential histology and 18F-fluoromisonidazole hypoxia imaging in renal cell carcinoma. Int J Oncol 41:1593–1600CrossRefPubMedCentralPubMed
16.
Zurück zum Zitat Wilhelm SM, Carter C, Tang L et al (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099–7109CrossRefPubMed Wilhelm SM, Carter C, Tang L et al (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099–7109CrossRefPubMed
17.
Zurück zum Zitat Ayers GD, McKinley ET, Zhao P et al (2010) Volume of Preclinical Xenograft Tumors Is More Accurately Assessed by Ultrasound Imaging Than Manual Caliper Measurements. J Ultrasound Med 29:891–901CrossRefPubMedCentralPubMed Ayers GD, McKinley ET, Zhao P et al (2010) Volume of Preclinical Xenograft Tumors Is More Accurately Assessed by Ultrasound Imaging Than Manual Caliper Measurements. J Ultrasound Med 29:891–901CrossRefPubMedCentralPubMed
18.
Zurück zum Zitat Zhou J, Zheng W, Cao L, Liu M, Han F, Li A (2010) Antiangiogenic tumor treatment: noninvasive monitoring with contrast pulse sequence imaging for contrast-enhanced grayscale ultrasound. Acad Radiol 17:646–651CrossRefPubMed Zhou J, Zheng W, Cao L, Liu M, Han F, Li A (2010) Antiangiogenic tumor treatment: noninvasive monitoring with contrast pulse sequence imaging for contrast-enhanced grayscale ultrasound. Acad Radiol 17:646–651CrossRefPubMed
19.
Zurück zum Zitat Yamashita YI, Shimada M, Hasegawa H et al (2001) Electroporation-mediated interleukin-12 gene therapy for hepatocellular carcinoma in the mice model. Cancer Res 61:1005–1012PubMed Yamashita YI, Shimada M, Hasegawa H et al (2001) Electroporation-mediated interleukin-12 gene therapy for hepatocellular carcinoma in the mice model. Cancer Res 61:1005–1012PubMed
20.
21.
Zurück zum Zitat Degasperi A, Birtwistle MR, Volinsky N, Rauch J, Kolch W, Kholodenko BN (2014) Evaluating strategies to normalise biological replicates of Western blot data. Plos One 9, e87293CrossRefPubMedCentralPubMed Degasperi A, Birtwistle MR, Volinsky N, Rauch J, Kolch W, Kholodenko BN (2014) Evaluating strategies to normalise biological replicates of Western blot data. Plos One 9, e87293CrossRefPubMedCentralPubMed
22.
Zurück zum Zitat Laufer J, Delpy D, Elwell C, Beard P (2007) Quantitative spatially resolved measurement of tissue chromophore concentrations using photoacoustic spectroscopy: application to the measurement of blood oxygenation and haemoglobin concentration. Phys Med Biol 52:141–168CrossRefPubMed Laufer J, Delpy D, Elwell C, Beard P (2007) Quantitative spatially resolved measurement of tissue chromophore concentrations using photoacoustic spectroscopy: application to the measurement of blood oxygenation and haemoglobin concentration. Phys Med Biol 52:141–168CrossRefPubMed
23.
Zurück zum Zitat Mallidi S, Watanabe K, Timerman D, Schoenfeld D, Hasan T (2015) Prediction of Tumor Recurrence and Therapy Monitoring Using Ultrasound-Guided Photoacoustic Imaging. Theranostics 5:289–301CrossRefPubMedCentralPubMed Mallidi S, Watanabe K, Timerman D, Schoenfeld D, Hasan T (2015) Prediction of Tumor Recurrence and Therapy Monitoring Using Ultrasound-Guided Photoacoustic Imaging. Theranostics 5:289–301CrossRefPubMedCentralPubMed
24.
Zurück zum Zitat Miyata A, Ishizawa T, Kamiya M, 9 et al (2014) Photoacoustic Tomography of Human Hepatic Malignancies Using Intraoperative Indocyanine Green Fluorescence Imaging. Plos One 7:9(11):e112667CrossRef Miyata A, Ishizawa T, Kamiya M, 9 et al (2014) Photoacoustic Tomography of Human Hepatic Malignancies Using Intraoperative Indocyanine Green Fluorescence Imaging. Plos One 7:9(11):e112667CrossRef
25.
Zurück zum Zitat Zhai B, Sun XY (2013) Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma. World J Hepatol 5:345–352CrossRefPubMedCentralPubMed Zhai B, Sun XY (2013) Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma. World J Hepatol 5:345–352CrossRefPubMedCentralPubMed
26.
Zurück zum Zitat Chang YS, Adnane J, Trail PA et al (2007) Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol 59:561–574CrossRefPubMed Chang YS, Adnane J, Trail PA et al (2007) Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol 59:561–574CrossRefPubMed
27.
Zurück zum Zitat Chen Y, Huang Y, Reiberger T et al (2014) Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice. Hepatology 59:1435–1447CrossRefPubMedCentralPubMed Chen Y, Huang Y, Reiberger T et al (2014) Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice. Hepatology 59:1435–1447CrossRefPubMedCentralPubMed
28.
Zurück zum Zitat Liang YJ, Zheng TS, Song RP et al (2013) Hypoxia-Mediated Sorafenib Resistance Can Be Overcome by EF24 Through Von Hippel-Lindau Tumor Suppressor-Dependent HIF-1 alpha Inhibition in Hepatocellular Carcinoma. Hepatology 57:1847–1857CrossRefPubMed Liang YJ, Zheng TS, Song RP et al (2013) Hypoxia-Mediated Sorafenib Resistance Can Be Overcome by EF24 Through Von Hippel-Lindau Tumor Suppressor-Dependent HIF-1 alpha Inhibition in Hepatocellular Carcinoma. Hepatology 57:1847–1857CrossRefPubMed
29.
Zurück zum Zitat Xu HT, Zhao L, Fang QJ et al (2014) MiR-338-3p Inhibits Hepatocarcinoma Cells and Sensitizes These Cells to Sorafenib by Targeting Hypoxia-Induced Factor 1 alpha. Plos One 9 Xu HT, Zhao L, Fang QJ et al (2014) MiR-338-3p Inhibits Hepatocarcinoma Cells and Sensitizes These Cells to Sorafenib by Targeting Hypoxia-Induced Factor 1 alpha. Plos One 9
30.
Zurück zum Zitat Liu LP, Ho RLK, Chen GG, Lai PBS (2012) Sorafenib Inhibits Hypoxia-Inducible Factor-1 alpha Synthesis: Implications for Antiangiogenic Activity in Hepatocellular Carcinoma. Clin Cancer Res 18:5662–5671CrossRefPubMed Liu LP, Ho RLK, Chen GG, Lai PBS (2012) Sorafenib Inhibits Hypoxia-Inducible Factor-1 alpha Synthesis: Implications for Antiangiogenic Activity in Hepatocellular Carcinoma. Clin Cancer Res 18:5662–5671CrossRefPubMed
31.
Zurück zum Zitat Zheng X, Wang X, Mao H, Wu W, Liu B, Jiang X (2015) Hypoxia-specific ultrasensitive detection of tumours and cancer cells in vivo. Nat Commun 6:5834CrossRefPubMed Zheng X, Wang X, Mao H, Wu W, Liu B, Jiang X (2015) Hypoxia-specific ultrasensitive detection of tumours and cancer cells in vivo. Nat Commun 6:5834CrossRefPubMed
32.
Zurück zum Zitat Harada H, Inoue M, Itasaka S et al (2012) Cancer cells that survive radiation therapy acquire HIF-1 activity and translocate towards tumour blood vessels. Nature Communications 3 Harada H, Inoue M, Itasaka S et al (2012) Cancer cells that survive radiation therapy acquire HIF-1 activity and translocate towards tumour blood vessels. Nature Communications 3
33.
Zurück zum Zitat Kim KR, Moon HE, Kim KW (2002) Hypoxia-induced angiogenesis in human hepatocellular carcinoma. J Mol Med (Berl) 80:703–714CrossRef Kim KR, Moon HE, Kim KW (2002) Hypoxia-induced angiogenesis in human hepatocellular carcinoma. J Mol Med (Berl) 80:703–714CrossRef
35.
Zurück zum Zitat Hu F, Deng X, Yang X et al (2015) Hypoxia upregulates Rab11-family interacting protein 4 through HIF-1 alpha to promote the metastasis of hepatocellular carcinoma. Oncogene 34:6007–6017CrossRefPubMed Hu F, Deng X, Yang X et al (2015) Hypoxia upregulates Rab11-family interacting protein 4 through HIF-1 alpha to promote the metastasis of hepatocellular carcinoma. Oncogene 34:6007–6017CrossRefPubMed
36.
Zurück zum Zitat Li H, Chen J, Zen W et al (2015) Effect of hypoxia inducible factor-1 antisense oligonucleotide on liver cancer. Int J Clin Exp Med 8:12650–12655PubMedCentralPubMed Li H, Chen J, Zen W et al (2015) Effect of hypoxia inducible factor-1 antisense oligonucleotide on liver cancer. Int J Clin Exp Med 8:12650–12655PubMedCentralPubMed
37.
Zurück zum Zitat Unruh A, Ressel A, Mohamed HG et al (2003) The hypoxia-inducible factor-1 alpha is a negative factor for tumor therapy. Oncogene 22:3213–3220CrossRefPubMed Unruh A, Ressel A, Mohamed HG et al (2003) The hypoxia-inducible factor-1 alpha is a negative factor for tumor therapy. Oncogene 22:3213–3220CrossRefPubMed
38.
Zurück zum Zitat Sugimoto K, Moriyasu F, Saito K et al (2013) Hepatocellular carcinoma treated with sorafenib: early detection of treatment response and major adverse events by contrast-enhanced US. Liver Int 33:605–615CrossRefPubMed Sugimoto K, Moriyasu F, Saito K et al (2013) Hepatocellular carcinoma treated with sorafenib: early detection of treatment response and major adverse events by contrast-enhanced US. Liver Int 33:605–615CrossRefPubMed
39.
Zurück zum Zitat Mejias M, Garcia-Pras E, Tiani C, Miquel R, Bosch J, Fernandez M (2009) Beneficial Effects of Sorafenib on Splanchnic, Intrahepatic, and Portocollateral Circulations in Portal Hypertensive and Cirrhotic Rats. Hepatology 49:1245–1256CrossRefPubMed Mejias M, Garcia-Pras E, Tiani C, Miquel R, Bosch J, Fernandez M (2009) Beneficial Effects of Sorafenib on Splanchnic, Intrahepatic, and Portocollateral Circulations in Portal Hypertensive and Cirrhotic Rats. Hepatology 49:1245–1256CrossRefPubMed
40.
Zurück zum Zitat Wilhelm S, Carter C, Lynch M et al (2006) Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 5:835–844CrossRefPubMed Wilhelm S, Carter C, Lynch M et al (2006) Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 5:835–844CrossRefPubMed
41.
Zurück zum Zitat Yang XZ, Dou S, Sun TM, Mao CQ, Wang HX, Wang J (2011) Systemic delivery of siRNA with cationic lipid assisted PEG-PLA nanoparticles for cancer therapy. J Control Release 156:203–211CrossRefPubMed Yang XZ, Dou S, Sun TM, Mao CQ, Wang HX, Wang J (2011) Systemic delivery of siRNA with cationic lipid assisted PEG-PLA nanoparticles for cancer therapy. J Control Release 156:203–211CrossRefPubMed
42.
Zurück zum Zitat Yan CH, Yang M, Li ZZ et al (2014) Suppression of orthotopically implanted hepatocarcinoma in mice by umbilical cord-derived mesenchymal stem cells with sTRAIL gene expression driven by AFP promoter. Biomaterials 35:3035–3043CrossRefPubMed Yan CH, Yang M, Li ZZ et al (2014) Suppression of orthotopically implanted hepatocarcinoma in mice by umbilical cord-derived mesenchymal stem cells with sTRAIL gene expression driven by AFP promoter. Biomaterials 35:3035–3043CrossRefPubMed
43.
Zurück zum Zitat Ben Mousa A (2008) Sorafenib in the treatment of advanced hepatocellular carcinoma. Saudi J Gastroenterol 14:40–42CrossRefPubMed Ben Mousa A (2008) Sorafenib in the treatment of advanced hepatocellular carcinoma. Saudi J Gastroenterol 14:40–42CrossRefPubMed
Metadaten
Titel
Non-invasive monitoring of the therapeutic response in sorafenib-treated hepatocellular carcinoma based on photoacoustic imaging
verfasst von
Seunghyun Lee
Jung Hoon Kim
Jae Hwan Lee
Jeong Hwa Lee
Joon Koo Han
Publikationsdatum
27.07.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
European Radiology / Ausgabe 1/2018
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-017-4960-3

Weitere Artikel der Ausgabe 1/2018

European Radiology 1/2018 Zur Ausgabe

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Klinikreform soll zehntausende Menschenleben retten

15.05.2024 Klinik aktuell Nachrichten

Gesundheitsminister Lauterbach hat die vom Bundeskabinett beschlossene Klinikreform verteidigt. Kritik an den Plänen kommt vom Marburger Bund. Und in den Ländern wird über den Gang zum Vermittlungsausschuss spekuliert.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.